HEALTH TECHNOLOGY

MindMed Announces a Collaboration with Datavant, a Leading Health data Connectivity Provider

Anurag Khadkikar | July 12, 2021

MindMed Announces a Collaboration with Datavant, a Leading Health data Connectivity Provider

MindMed, a leading biotech firm developing psychedelic-inspired therapies, and Datavant, Inc., a leader in assisting healthcare organizations in safely connecting their data, announced a collaboration in which MindMed will use Datavant's privacy-protecting technology to link MindMed's clinical trial data to external data from both clinical and real-world sources. In addition, MindMed intends to use Datavant's connecting technology across the drug lifecycle, including discovery, clinical development, and commercialization.

 

MindMed will create broad and comprehensive datasets via data linking to understand better the real-world treatment, service usage, and healthcare experiences of patients with psychiatric and drug use disorders. This data, as well as a better understanding of both the relevant illness and the pathways of treatment that patients take, will assist MindMed's clinical trial planning, execution, and preparation for commercialization of its novel molecules.

 

About MindMed

MindMed is a clinical-stage biotech company that discovers, develops, and sells psychedelic-inspired medicines and therapies to treat addiction and mental disease. The company is building a compelling drug development pipeline of novel treatments based on psychedelic drugs such as psilocybin, LSD, MDMA, DMT, and 18-MC, an ibogaine derivative. MindMed's executive team brings extensive biopharmaceutical expertise to the company's approach to creating the next generation of psychedelic-inspired medicines and therapies.

 

About Datavant

The goal of Datavant is to connect the world's health data to enhance patient outcomes. Datavant aims to minimize the friction associated with data sharing in the healthcare sector by developing the technology that preserves patients' privacy while allowing the linkage of de-identified patient records across datasets. Datavant is based in San Francisco.
 

Spotlight

Given the widespread adoption of electronic health record (EHR) systems and health IT generally, healthcare organizations now are faced with the daunting challenge of securing these systems to keep patients safe, data secure and systems running efficiently.


Other News

HEALTH TECHNOLOGY

PulsePoint Releases Next Generation Health Media Platform With Advanced Automation And AI

PulsePoint | July 06, 2021

PulsePoint, a technology company revolutionizing health decision-making in real-time, today announced the next generation launch of its digital media buying platform, Life by PulsePoint™. Its enhanced AI and automation simplifies and supercharges the media planning, activation, and optimization processes. Designed for the self-serve programmatic trader, these updates promote efficiencies and surface predictive and in-flight campaign analytics for quick strategic decisioning to yield higher media return on investment. Built upon PulsePoint's extensive data foundation, Genome™, that proactively uses microdata to capture attention when intent is signal...

Read More

HEALTH TECHNOLOGY

Future Health announced today that it has completely digitalised its annual in-person event at ExCeL London

Future Health | March 02, 2021

Future Health has completely rebranded during lockdown, and the flagship face-to-face event Future Health Innovations at ExCeL is now complemented by a global virtual conference series, under the brand UK Health Week. Free for delegates to attend, it is CPD and CME accredited. Participants will be able to connect, meet buyers and partake in cross border purchasing, education and deal making, enabling an increased ROI and profitable encounters with its AI powered networking software. Further Health Weeks are being rolled out around the world over the course of the coming months, and will be territory specific. Dawn Barclay-Ross, Event Director commented: “I think ...

Read More

HEALTH TECHNOLOGY

L2Mtech GmbH Receives CE Mark Approval on 6(SIX) products for Cardiovascular and Endovascular Applications

L2Mtech | February 17, 2021

CE Mark Approval for LimusTrack™, Sirolimus Eluting Coronary Stent System for Cardiovascular Applications. CE Mark Approval for LomiFlow™, Paclitaxel Drug Eluting Balloon for Cardiovascular Applications CE Mark Approval for PearlFlow™, Paclitaxel Drug Elutin Balloon for Endovascular Applications CE Mark Approval for PearlFlow NS™, Self Expandable Nitinol Stent System for Endovascular Applications CE Mark Approval for FlexiTrack 018™, Peripheral Balloon Catheter for Endovascular Applications CE Mark Approval for

Read More

CMS to pay providers via MIPS for participating in COVID-19 drug treatment trials

CMS | April 21, 2020

Clinicians can earn a credit via the Merit-based Incentive Payment System (MIPS) if they participate in a clinical trial and report clinical information on COVID-19, the Trump administration announced late Monday. The Centers for Medicare & Medicaid Services (CMS) said Monday that the goal of the new credit is to provide data that will be vital to making treatments to combat the virus. “The best scientific and medical minds in the world are working night and day to find treatments to combat coronavirus,” CMS Administrator Seema Verma said in a statement Monday. “But without solid data, their efforts are liable to run against a brick wall.”...

Read More

Spotlight

Given the widespread adoption of electronic health record (EHR) systems and health IT generally, healthcare organizations now are faced with the daunting challenge of securing these systems to keep patients safe, data secure and systems running efficiently.

Resources

Events